Financials Brainstorm Cell Therapeutics Inc.
Equities
BCLI
US10501E2019
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.42 USD | -3.34% | -20.75% | +54.43% |
04-17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
04-17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 29.69 | - | - |
Enterprise Value (EV) 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 29.69 | 29.69 | 29.69 |
P/E ratio | -4.04 x | -4.23 x | -5.88 x | -2.48 x | -0.68 x | -1.55 x | -1.16 x | -1.05 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 22,606 | 31,568 | 36,278 | 36,542 | 48,982 | 68,342 | - | - |
Reference price 2 | 4.280 | 4.525 | 4.000 | 1.640 | 0.2730 | 0.4345 | 0.4345 | 0.4345 |
Announcement Date | 18/02/20 | 04/02/21 | 28/03/22 | 30/03/23 | 01/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -23 | -31.68 | -24.54 | -24.82 | -21.44 | -21.9 | -27.43 | -31.1 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
Net income 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -1.060 | -1.070 | -0.6800 | -0.6600 | -0.4000 | -0.2800 | -0.3750 | -0.4150 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 18/02/20 | 04/02/21 | 28/03/22 | 30/03/23 | 01/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.277 | -6.212 | -5.475 | -7.591 | -6.841 | -4.915 | -5.151 | -5.449 | -6.035 | -4.804 | -4.5 | -5.2 | -5.8 | -6.4 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.336 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -4.5 | -5.2 | -5.8 | -6.4 |
Net income 1 | -5.336 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -4.5 | -5.2 | -5.8 | -6.4 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1500 | -0.1700 | -0.1500 | -0.1900 | -0.1900 | -0.1300 | -0.1400 | -0.1300 | -0.0300 | -0.1100 | -0.0700 | -0.0700 | -0.0600 | -0.0700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 15/11/21 | 28/03/22 | 16/05/22 | 15/08/22 | 14/11/22 | 30/03/23 | 15/05/23 | 14/08/23 | 14/11/23 | 01/04/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 18/02/20 | 04/02/21 | 28/03/22 | 30/03/23 | 01/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.43% | 29.69M | |
+19.47% | 42.68B | |
-3.09% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.19% | 24.94B | |
-20.28% | 18.96B | |
+30.21% | 12.3B | |
-2.62% | 11.95B | |
-2.81% | 11.55B |
- Stock Market
- Equities
- BCLI Stock
- Financials Brainstorm Cell Therapeutics Inc.